Table 1.
Clinical characteristics of patients with 19Del, 21L858R, and WT EGFR mutation status in the training and testing cohorts
| Training cohort (n = 306) | Testing cohort (n = 93) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19Del | 21L858R | WT | p-value | 19Del | 21L858R | WT | p-value | |||||
| (n = 120) | (n = 108) | (n = 78) | (19Del/WT) | (21L858R/WT) | (19Del/21L858R) | (n = 30) | (n = 30) | (n = 33) | (19Del/WT) | (21L858R/WT) | (19Del/21L858R) | |
| Sex | ||||||||||||
| Male | 47 (39.2%) | 41 (38.0%) | 40 (51.3%) | 0.093 | 0.071 | 0.852 | 15 (50.0%) | 14 (46.7%) | 20 (60.6%) | 0.397 | 0.268 | 0.796 |
| Female | 73 (60.8%) | 67 (62.0%) | 38 (48.7%) | 15 (50.0%) | 16 (53.3%) | 13 (39.4%) | ||||||
| Age (years, mean ± SD) | 56.7 ± 11.2 | 60.7 ± 10.0 | 52.3 ± 12.5 | 0.010* | < 0.001* | 0.005* | 58.2 ± 12.2 | 60.0 ± 11.1 | 62.1 ± 8.2 | 0.133 | 0.382 | 0.552 |
| Alcohol consumption | ||||||||||||
| Yes | 28 (23.3%) | 21 (19.4%) | 29 (37.2%) | 0.036* | 0.007* | 0.475 | 5 (16.7%) | 3 (10.0%) | 19 (57.6%) | 0.001* | < 0.001* | 0.448 |
| No | 92 (76.7%) | 87 (80.6%) | 49 (62.8%) | 25 (83.3%) | 27 (90.0%) | 14 (42.4%) | ||||||
| Smoking | ||||||||||||
| Yes | 31 (25.8%) | 25 (23.2%) | 31 (39.7%) | 0.039* | 0.015* | 0.638 | 6 (20.0%) | 3 (10.0%) | 19 (57.6%) | 0.002* | < 0.001* | 0.278 |
| No | 89 (74.2%) | 83 (76.9%) | 47 (60.3%) | 24 (80.0%) | 27 (90.0%) | 14 (42.4%) | ||||||
Differences were assessed by t test or χ2 test. 19 Del 19 deletion, 21L858R 21-point mutation, EGFR Epidermal growth factor receptor, SD Standard deviation, WT Wild-type
*p < 0.05